Quercetin Flavonoid

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: immunity inflammation heart

Research Overview

Across the abstracts, quercetin (and key derivatives such as rutin/quercetin-3-rutinoside) is most studied in three intersecting areas: (1) inflammation biology and inflammation-associated chronic diseases, where quercetin is positioned among plant-derived anti-inflammatory phytochemicals that modulate cytokines and inflammatory signaling; (2) oncology, where mechanistic work emphasizes pleiotropic signaling effects, apoptosis induction, antiangiogenic/antimetastatic activity, and potential to sensitize tumors to chemo- and radiotherapy; and (3) formulation/nanotechnology, reflecting a major translational focus on overcoming quercetin’s low bioavailability and unfavorable physicochemical properties via nano-formulations and carrier systems (e.g., hybrid nanocomposites for delivery/sensing; mesoporous silica vehicles for topical stabilization and performance). A distinct, mechanistically targeted cardiovascular/thrombosis line is also highlighted: quercetin-3-rutinoside inhibition of protein disulfide isomerase (PDI) as an antithrombotic strategy supported by preclinical thrombosis models and motivating clinical trial development of PDI antagonists.

The strongest evidence in these abstracts supports robust preclinical mechanistic activity rather than definitive clinical efficacy. In cancer, evidence is strongest for multi-target cellular effects and dose-dependent (hormetic) behavior—antioxidant/chemopreventive actions at lower concentrations and pro-oxidant/cytotoxic actions at higher concentrations—along with consistent in vitro findings of apoptosis and pathway modulation; one review notes supportive animal data and a phase I clinical trial suggesting feasibility/safety, but not yet confirmatory efficacy. In thrombosis, the PDI-inhibition mechanism and thrombus-blocking effects are supported in preclinical studies and have a clear translational path (drug class development and trial design considerations). In dermatologic/photoprotection applications, in vitro formulation studies provide comparatively strong evidence that engineered carriers (e.g., octyl-functionalized MCM-41 silica) can improve quercetin stability and maintain antioxidant function, supporting product-oriented development where local delivery is feasible.

Key gaps center on translation, dosing, and delivery. More research is needed to (i) establish clinically meaningful efficacy across indications with well-designed human trials (beyond early-phase safety), (ii) define exposure–response relationships given hormesis and the high concentrations often required for in vitro anticancer effects, (iii) standardize formulations and characterize pharmacokinetics/bioavailability for quercetin versus derivatives (e.g., rutin) and for nano-enabled systems, and (iv) clarify long-term safety and off-target effects, particularly for chronic use and for novel nanocomposites. Mechanistically, further work is also needed to elucidate how PDI inhibition translates to platelet activation and fibrin formation in humans, and to determine which patient populations and endpoints are most appropriate for antithrombotic trials. Overall, the literature reflected here is mechanistically rich and formulation-driven, with clinical validation remaining the principal unmet need.

1. What conditions has Quercetin Flavonoid been studied for?

  • Inflammation and inflammation-associated chronic diseases: Reviewed as a plant-derived anti-inflammatory phytochemical with preclinical and some clinical evaluation across inflammation-linked disorders (e.g., arthritis, diabetes, obesity, cancer, cardiovascular diseases are mentioned as associated with chronic low-grade inflammation in the review context).

  • Cancer (chemoprevention and therapy support): Broad oncology-focused review describes anticancer actions and potential roles in prevention, treatment, and as an adjunct to chemo/radiotherapy; also notes a phase I clinical trial and animal experiments.

  • Prostate cancer (cell-line model): Rutin (a quercetin glycoside) studied with 5-fluorouracil (5-FU) in PC3 prostate cancer cells.

  • Thrombosis (blood clot formation): Quercetin-3-rutinoside reported to inhibit protein disulfide isomerase (PDI) and block thrombus formation in preclinical studies; this finding motivated clinical trial development of PDI antagonists.

  • UV-related skin oxidative damage (topical use): Quercetin loaded into mesoporous silica (MCM-41) studied in vitro for stability, diffusion, and antioxidant performance relevant to photoprotection.

  • High-altitude cerebral edema (HACE): Rat model comparing quercetin vs dexamethasone for hypoxia-induced cerebral edema and inflammation.

  • Febrile seizures with prenatal stress: Rat model of inflammation-associated febrile seizures; quercetin given at seizure onset and inflammatory markers measured.

  • Antimicrobial/antibacterial research (indirect evidence): Quercetin appears as a component in a plant extract profiled by NMR in a study targeting carbapenem-resistant Acinetobacter baumannii; separate work in the same abstract emphasizes ROS-mediated killing by gallate-based silver nanoparticles rather than isolating quercetin’s effect.

  • Nanomedicine/drug delivery and sensing: Quercetin and derivatives (including rutin) discussed as candidates for hybrid nanocomposites to improve delivery and potentially antimicrobial performance (conceptual/technology-focused abstract).

2. Does it work in treating those conditions? Summarize the evidence.

  • Inflammation (general): The anti-inflammatory review describes quercetin as a representative anti-inflammatory phytochemical and notes that some phytochemicals have been evaluated at preclinical and clinical levels. However, the abstract does not provide specific clinical outcomes for quercetin itself, so efficacy for particular inflammatory diseases cannot be confirmed from these abstracts alone.

  • High-altitude cerebral edema (HACE): In rats exposed to hypoxia (25,000 ft for 24 h), oral quercetin 50 mg/kg given 1 hour prior significantly reduced brain water content and transvascular leakage (P < 0.001 vs hypoxia control) and reduced NFκB more than dexamethasone (P < 0.05). Histology showed absence of edema/inflammation in quercetin-treated hypoxic rats. This is promising but is animal-only evidence and prophylactic (pre-exposure) dosing.

  • Febrile seizures (prenatally stressed rat model): Quercetin suppressed a pro-inflammatory marker (interleukin-1β) and attenuated febrile seizures in this model. This supports anti-inflammatory and anticonvulsant effects in animals, but does not establish effectiveness in children with febrile seizures.

  • Thrombosis: A review reports that quercetin-3-rutinoside inhibits PDI and blocks thrombus formation in preclinical studies, helping motivate clinical trials of PDI antagonists. The abstract does not report completed human trial outcomes for quercetin/rutin as an antithrombotic.

  • Cancer (general): The oncology review states quercetin has anticancer actions in vitro and in vivo, can induce apoptosis in cancer cells, and may sensitize tumors to chemo/radiotherapy while protecting non-cancer cells; it also mentions safety/potential usefulness documented in animal experiments and a phase I clinical trial. Phase I trials primarily address safety/tolerability and dosing, not definitive efficacy, and the abstract provides no tumor-response results.

  • Prostate cancer (PC3 cells; rutin + 5-FU): In vitro, rutin and 5-FU showed synergy (combination index 0.33). The combination increased apoptosis and p53 expression and decreased Bcl-2 and colony counts versus separate treatment. This supports a mechanistic synergy in a cell line, but it is not clinical evidence and used high micromolar/millimolar concentrations (IC50s: rutin 900 μM; 5-FU 3 mM).

  • Skin photoprotection/antioxidant performance (topical formulation): In vitro, immobilizing quercetin on mesoporous silica (especially octyl-functionalized) increased storage and photostability without undermining antioxidant efficacy, suggesting formulation can improve performance. This does not directly demonstrate reduced UV damage in humans.

  • Antimicrobial effects: The nanocomposite abstract suggests antimicrobial potential and improved delivery, but provides no clear efficacy results in the provided text. The A. baumannii abstract identifies quercetin in an active plant extract, but the mechanistic validation emphasized ROS-mediated damage and then validated antimicrobial activity with gallate-based silver nanoparticles, not purified quercetin—so quercetin’s standalone efficacy is not established here.

3. What health benefits does it have?

  • Anti-inflammatory activity: Multiple abstracts link quercetin to downregulation of inflammatory pathways/mediators. In HACE rats, quercetin reduced NFκB signaling more than dexamethasone and reduced edema/inflammation markers.

  • Antioxidant effects (and context-dependent pro-oxidant effects): The oncology review describes a biphasic (hormetic) dose-response: antioxidant at low concentrations (chemopreventive potential) and pro-oxidant at high concentrations (possible chemotherapeutic relevance). The skincare formulation study supports preserved antiradical/chelating activity with improved stability.

  • Potential anticancer mechanisms: The oncology review describes apoptosis induction, antiangiogenic and antimetastatic properties, gene-expression and epigenetic effects, and potential to reverse treatment resistance; the prostate cancer cell study (rutin + 5-FU) supports apoptosis/p53 upregulation and Bcl-2 downregulation in vitro.

  • Potential antithrombotic mechanism: Quercetin-3-rutinoside is reported to inhibit PDI and block thrombus formation in preclinical models, suggesting a plausible pathway for reducing thrombosis risk (human benefit not established in these abstracts).

  • Neuroprotective/anti-edema effects in hypoxia models: In HACE rats, quercetin reduced brain edema and vascular leakage and improved histopathology.

  • Potential anticonvulsant benefit in inflammation-linked seizures (animal data): In prenatally stressed rat pups, quercetin reduced IL-1β and attenuated febrile seizures.

  • Formulation advantages (bioavailability/stability): Both the oncology review and the topical silica study highlight that quercetin’s usefulness is limited by physicochemical properties/low bioavailability, and that nano-/carrier formulations can improve stability and performance.

4. Does it have any downsides or side effects?

  • Low bioavailability and unfavorable physicochemical properties: The oncology review states low bioavailability limits clinical use as an antitumor agent; the skincare study similarly notes unfavorable physicochemical properties limiting usefulness, motivating carrier systems (e.g., mesoporous silica) to improve stability/performance.

  • Dose-dependent (biphasic) effects: The oncology review describes hormetic behavior—antioxidant at low concentrations but pro-oxidant at high concentrations. This implies that higher doses could theoretically increase oxidative stress, which may be beneficial in killing cancer cells but could also pose safety/tolerability concerns depending on context; the abstract does not quantify risk in humans.

  • Evidence limitations for safety claims: The HACE rat study states quercetin attenuated edema/inflammation “without any side effects of steroid therapy,” but this is a comparison to dexamethasone in rats and does not establish that quercetin is side-effect free in humans.

  • Potential drug-interaction considerations (suggestive, not proven here): The prostate cancer cell study suggests synergy between rutin and 5-FU in vitro. While not a demonstrated clinical interaction, it raises the possibility that quercetin derivatives could modulate responses to chemotherapy—potentially beneficial or harmful—requiring clinical evaluation.

  • Antimicrobial/nanocomposite toxicity not resolved: The nanoscience abstract mentions toxicity as a limitation for flavonoids at the molecular level and proposes nanocomposites to improve properties, but provides no specific adverse-event data for quercetin itself.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report pharmacogenomic findings (i.e., specific genetic variants that predict better response, higher risk, or altered metabolism of quercetin/rutin).

  • No variant-specific efficacy or safety data: None of the abstracts mention genotype-stratified outcomes or gene variants affecting quercetin response.

  • Mechanistic hints but not pharmacogenomics: The prostate cancer cell study reports increased p53 expression and decreased Bcl-2 with rutin + 5-FU, and the HACE study reports NFκB inhibition. These are pathway effects, but they are not linked to inherited genetic variation in the abstracts.

References

  1. Phytochemicals in the treatment of inflammation-associated diseases: the journey from preclinical trials to clinical practice.
    Akib Nisar, Suresh Jagtap, Suresh Vyavahare, Manasi Deshpande, Abhay Harsulkar, Prabhakar Ranjekar, Om Prakash (2023) - Frontiers in pharmacology
  2. Application of quercetin flavonoid based hybrid nanocomposites: A review.
    Biswajit Parhi, Debasrita Bharatiya, Sarat K Swain (2020) - Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society
  3. Synergetic Impact of Combined 5-Fluorouracil and Rutin on Apoptosis in PC3 Cancer Cells through the Modulation of P53 Gene Expression
    Atefeh Satari, Sayed Asadollah Amini, Elham Raeisi, Yves Lemoigne, Esfandiar Heidarian (2019)
  4. Therapeutic implications of protein disulfide isomerase inhibition in thrombotic disease.
    Robert Flaumenhaft, Bruce Furie, Jeffrey I Zwicker (2015) - Arteriosclerosis, thrombosis, and vascular biology
  5. Potential of the Flavonoid Quercetin to Prevent and Treat Cancer - Current Status of Research.
    Neuwirthová Jana, Gál Břetislav, Smilek Pavel, Urbánková Pavla (2018) - Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti
  6. Stabilization of quercetin flavonoid in MCM-41 mesoporous silica: positive effect of surface functionalization.
    Gloria Berlier, Lucia Gastaldi, Elena Ugazio, Ivana Miletto, Patrizia Iliade, Simona Sapino (2013) - Journal of colloid and interface science
  7. Quercetin as a prophylactic measure against high altitude cerebral edema.
    Himadri Patir, S K S Sarada, Saumya Singh, Titto Mathew, Bhagwat Singh, Anju Bansal (2012) - Free radical biology & medicine
  8. The Effect of Quercetin on Pro- and Anti-Inflammatory Cytokines in a Prenatally Stressed Rat Model of Febrile Seizures.
    Nombuso Valencia Pearl Mkhize, Lihle Qulu, Musa Vuyisile Mabandla (2017) - Journal of experimental neuroscience
  9. Assessment of Molecular Mechanism of Gallate-Polyvinylpyrrolidone-Capped Hybrid Silver Nanoparticles against Carbapenem-ResistantAcinetobacter baumannii
    Monalisa Tiwari, Pawan Kumar, Kiran Kumar Tejavath, Vishvanath Tiwari (2020)
  10. Antihypertensive effect of the methanolic extract from Eruca sativa Mill., (Brassicaceae) in rats: Muscarinic receptor-linked vasorelaxant and cardiotonic effects.
    Umme Salma, Taous Khan, Abdul Jabbar Shah (2018) - Journal of ethnopharmacology
  11. Effect of quercetin and Abelmoschus esculentus (L.) Moench on lipids metabolism and blood glucose through AMPK-α in diabetic rats (HFD/STZ).
    Zohreh Nasrollahi, Kahin ShahaniPour, Ramesh Monajemi, Ali Mohammad Ahadi (2022) - Journal of food biochemistry
  12. Effect of quercetin against lindane induced alterations in the serum and hepatic tissue lipids in wistar rats.
    Viswanadha Vijaya Padma, Gurusamy Lalitha, Nicholson Puthanveedu Shirony, Rathinasamy Baskaran (2012) - Asian Pacific journal of tropical biomedicine
  13. Efficacy of quercetin flavonoid in recovering the postbleaching bond strength of orthodontic brackets: A preliminary study.
    Mana Shamsedin, Valiollah Arash, Masoud Babaei Jahromi, Ali Akbar Moghadamnia, Manouchehr Rahmati Kamel, Fariba Ezoji, Ali Bijani, Samira Kavoli, Tania Ghasemi, Gholamhossein Ramezani (2017) - Journal of orthodontic science
  14. Quercetin reduced the formation of N-acetyl-p-benzoquinoneimine, a toxic metabolite of paracetamol in rats and isolated rat hepatocytes.
    Ravindrababu Pingili, A Krishnamanjari Pawar, Siva Reddy Challa (2019) - Phytotherapy research : PTR
  15. Antioxidant effect on shear bond strength of orthodontic brackets after tooth bleaching: A scoping review of in vitro studies.
    Shaimaa S Zaki, Sayed M Ghorab, Marwa S Shamaa (2023) - International orthodontics
  16. Antimicrobial evaluation of silver nanoparticles using extracts of Crescentia cujete L.
    M A Sánchez, J A Fiscal Ladino (2023) - Brazilian journal of biology = Revista brasleira de biologia
  17. Self-assembly of Hyaluronic Acid-Cu-Quercetin flavonoid nanoparticles: synergistic chemotherapy to target tumors.
    Hanxun Yue, Xuan Zhao, Qin Yong, Min Shi, Xiaofeng Jiang, Yating Zhang, Xian Yu (2023) - PeerJ
  18. Effect of quercetin on the amiloride-bovine serum albumin interaction using spectroscopic methods, molecular docking and chemometric approaches.
    Mandakini Shinde, Kishor Kale, Keshav Kumar, Divya Ottoor (2021) - Luminescence : the journal of biological and chemical luminescence
  19. [Effects of quercetin on multidrug resistance and expression of related genes in human erythroleukemic K562/a cells].
    Yan-Qiu Han, Lin-Juan Cao, Hong-Jun Hao, Yong-Jin Shi (2011) - Zhongguo shi yan xue ye xue za zhi


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!